• Avalo Therapeutics amended employment agreements for CEO Garry A. Neil, CFO Christopher Sullivan, CMO Mittie Doyle, and CBO Taylor Boyd, effective June 12, 2026.
• Outside a change-in-control window, termination without cause or for good reason triggers 12 months’ base-salary severance, or 18 months for Neil.
• Within three months before through 12 months after a change in control, severance shifts to 1x base salary plus 1x target bonus, or 1.5x salary for Neil.
• Change-in-control terminations also provide full acceleration of time-based equity awards; vested options remain exercisable for up to 12 months for Neil, Sullivan.
• Payments may be cut back to avoid Section 280G excise-tax exposure when that produces a higher after-tax amount for the executive.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Avalo Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001534120-26-000040), on June 12, 2026, and is solely responsible for the information contained therein.